Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T21:57:33.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    A 403 Forbidden page appears, replacing the study details and related sections with an error screen, making the record inaccessible to users.
    Difference
    19%
    Check dated 2026-09-20T19:51:47.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.5 to v3.6.6. This indicates a new build/version of the page.
    Difference
    0.1%
    Check dated 2026-08-30T21:41:13.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page's revision metadata was updated from v3.6.4 to v3.6.5, indicating a minor update to the page's revision number.
    Difference
    0.1%
    Check dated 2026-08-09T08:53:42.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    The page revision tag was updated to v3.6.4, indicating a minor update to the ClinicalTrials.gov record. No study data or criteria appear to be altered.
    Difference
    0.1%
    Check dated 2026-07-25T18:15:34.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    The study's recruitment status was updated to 'Active, not recruiting' with a note that no participants are being sought, indicating enrollment has closed. Several investigator and contact details were removed, reducing publicly listed study contacts.
    Difference
    4%
    Check dated 2026-07-11T14:29:21.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.